KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio: 2009-2025

Historic Equity Ratio for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to 0.77.

  • Regeneron Pharmaceuticals' Equity Ratio fell 1.60% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 1.60%. This contributed to the annual value of 0.78 for FY2024, which is 0.99% down from last year.
  • According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Equity Ratio is 0.77, which was down 1.62% from 0.78 recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Equity Ratio's 5-year high stood at 0.79 during Q1 2024, with a 5-year trough of 0.67 in Q1 2021.
  • Its 3-year average for Equity Ratio is 0.78, with a median of 0.78 in 2025.
  • Data for Regeneron Pharmaceuticals' Equity Ratio shows a peak YoY increase of 15.81% (in 2021) and a maximum YoY decrease of 12.48% (in 2021) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.74 in 2021, then rose by 5.13% to 0.78 in 2022, then rose by 1.21% to 0.79 in 2023, then dropped by 0.99% to 0.78 in 2024, then declined by 1.60% to 0.77 in 2025.
  • Its Equity Ratio stands at 0.77 for Q3 2025, versus 0.78 for Q2 2025 and 0.78 for Q1 2025.